Biological outcomes in disease-modification trials

被引：0
|
作者：
Galasko, D [1 ]
机构：
[1] UCSD, Dept Neurosci, San Diego, CA USA
来源：
NEUROBIOLOGY OF AGING | 2004年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
37
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [1] Applications of neuroimaging to disease-modification trials in Alzheimer's disease
    Fleisher, Adam S.
    Donohue, Michael
    Chen, Kewei
    Brewer, James B.
    Aisen, Paul S.
    BEHAVIOURAL NEUROLOGY, 2009, 21 (1-2) : 129 - 136
  • [2] Prodromal Parkinson's disease: hype or hope for disease-modification trials?
    Mahlknecht, Philipp
    Marini, Kathrin
    Werkmann, Mario
    Poewe, Werner
    Seppi, Klaus
    TRANSLATIONAL NEURODEGENERATION, 2022, 11 (01)
  • [3] Early Crohn disease: a proposed definition for use in disease-modification trials
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Colombel, Jean-Frederic
    Sandborn, William J.
    GUT, 2010, 59 (02) : 141 - 147
  • [4] Prodromal Parkinson's disease: hype or hope for disease-modification trials?
    Philipp Mahlknecht
    Kathrin Marini
    Mario Werkmann
    Werner Poewe
    Klaus Seppi
    Translational Neurodegeneration, 11
  • [5] "Disease-modification" trials in Parkinson disease: Target populations, endpoints and study design
    Rascol, Olivier
    NEUROLOGY, 2009, 72 : S51 - S58
  • [6] Preparing for Disease-Modification Trials in Degenerative Cerebellar Ataxias: Which Endpoints to Choose?
    Maas, Roderick P. P. W. M.
    MOVEMENT DISORDERS, 2023, 38 (06) : 917 - 923
  • [7] Disease-Modification in Epilepsy by Nonpharmacological Methods
    Jones, Nigel C.
    EPILEPSY CURRENTS, 2018, 18 (01) : 45 - 46
  • [8] Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
    Le Berre, Catherine
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (05) : 1452 - 1460
  • [9] Mixed results for disease-modification strategies for Alzheimer's disease
    Alisa Opar
    Nature Reviews Drug Discovery, 2008, 7 : 717 - 718
  • [10] ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease
    D J Stone
    C Molony
    C Suver
    E E Schadt
    W Z Potter
    The Pharmacogenomics Journal, 2010, 10 : 161 - 164
12345